Phase 3 data from the SYNCHRONIZE-1 trial shows the experimental drug reducing visceral and liver fat while preserving lean muscle mass in adults with obesity.
Most weight loss medications work by suppressing appetite. Survodutide does that too, but the experimental drug developed by Boehringer Ingelheim is drawing attention for what it appears to do beyond the scale.
New data from the phase 3 SYNCHRONIZE-1 trial, presented at the 2026 American Diabetes Association Scientific Sessions, showed that adults with obesity or overweight who took Survodutide lost an average of up to 16.6% of their body weight over 76 weeks. The placebo group lost 3.2% over the same period. That gap alone would mark the drug as competitive in a crowded field. What researchers found when they looked closer at where that weight came from is what has made the results particularly notable.
Survodutide
Survodutide is a dual glucagon and GLP-1 receptor agonist, meaning it activates two separate biological pathways simultaneously. GLP-1 activation reduces appetite and slows digestion, a mechanism shared by several already-approved obesity drugs. The glucagon component adds something different it accelerates fat metabolism and increases energy expenditure, targeting fat stores more aggressively than GLP-1 alone.
In the SYNCHRONIZE-1 trial, which enrolled 725 adults, that combination produced measurable reductions in two types of fat that carry significant health risk. Visceral fat, the kind that accumulates around internal organs and drives cardiovascular and metabolic disease, fell by up to 34%. Liver fat dropped by up to 63.1%. Critically, lean body mass remained largely intact, addressing one of the more persistent concerns about rapid weight loss treatments, which can strip away muscle along with fat.
Liver disease outcomes draw particular attention
A parallel study, SYNCHRONIZE-MASLD, focused specifically on adults with metabolic dysfunction-associated steatotic liver disease, a condition more commonly known as fatty liver disease. Among the 216 participants in that 48-week trial, up to 84.2% of those taking Survodutide reduced liver fat by at least 30%. In the placebo group, 24% achieved the same threshold. Around 60% of participants on Survodutide normalized their liver fat levels entirely.
Fatty liver disease affects a substantial share of people with obesity and can progress to cirrhosis or liver failure if left unaddressed. Effective pharmaceutical options for the condition remain limited, which makes Survodutide’s liver-specific results meaningful beyond its weight loss profile.
What the lead investigator said
Professor Carel le Roux, the global coordinating investigator of the SYNCHRONIZE-1 trial, described the pattern of fat loss as the most significant finding from the study. The reductions in metabolically harmful fat deposits alongside preserved lean mass pointed to broader metabolic benefits than those typically measured by weight loss alone.
Side effects and the road to approval
Survodutide is not yet approved by any regulatory agency and remains an investigational therapy. Gastrointestinal side effects including nausea, vomiting, and diarrhea were reported by a meaningful portion of participants, and the discontinuation rate among those taking the drug was higher than in the placebo group.
Those figures are consistent with what has been observed across the GLP-1 drug class broadly, though they represent a real barrier for some patients. Boehringer Ingelheim has not announced a timeline for regulatory submission, and additional trials are ongoing.
For researchers watching the obesity drug space, the SYNCHRONIZE results place Survodutide firmly in contention as a treatment that addresses metabolic disease from multiple angles at once, a capability that the current approved options do not fully replicate.
